Abstract Submission & Guidelines

Abstract Submission & Guidelines


Submission Deadline: Tuesday, 16 January 2024 – 23:59 SAST

16 January 2024


1 February 2024**


13 February 2024



Regular Abstract Submission

Abstract Submission Opens 15 May 2023
Abstract Submission Deadline 12 September 2023 (23:59 SAST)
Abstract Submission Extended Deadline 26 September 2023 (23:59 SAST)
Abstract Notifications* 30 October 2023 / 30 November 2023
Registration Deadline for Regular Submission Abstract Presenters 6 December 2023

Late-Breaking Abstract Submission

Late-Breaking Abstract Submission Opens 30 October 2023
Late-Breaking Abstract Submission Deadline (updated)*** 16 January 2024
Late-Breaking Abstract Notifications** 1 February 2024
Registration Deadline for Late-Breaking Abstract Presenters 13 February 2024

*The first round of acceptance/rejection notifications were sent to all presenting authors on 30 October 2023. The follow-up notifications regarding the acceptance type of each abstract, as well as travel grant application notifications where applicable, were sent out between 23 and 30 November 2023.
**Please note that all efforts are made to send the late-breaking abstract notifications by the announced date. In case of any delays, an updated timeline will be poster here. We thank you in advance for your understanding and cooperation!
***Please note that there will be no extension to the late-breaking abstract submission deadline. No abstracts will be accepted past 16 January 2024. 


To view the full abstract submission guidelines, please click on the orange buttons below for each category.


  • All abstracts must be submitted via the official ISPPD-13 abstract submission portal (URL available during the submission period). Please note that the Meeting Organisers are not able to accept abstracts submitted via e-mail.
  • Abstracts must be received by the announced deadline. Abstracts received after the deadline will not be considered.
  • Abstracts must be original and must not have been published or presented at any other international meeting prior to ISPPD-13.
  • All abstracts must be submitted in English.
  • Each abstract should not exceed 250 words.
  • The abstract title should not exceed 25 words and should be UPPER CASE.
  • Each author can submit a maximum of five (5) abstracts and each person can be assigned as the presenter of a maximum of five (5) abstracts.

The following structure must be followed when submitting an abstract:

  1. Background
  2. Methods
  3. Results
  4. Conclusions


Presentation Type

Please choose the presentation format you would prefer. Please note that the Meeting Organisers will determine the final format based on content and programme time limitations.

  • Oral presentation (about 10-minutes including Q&A) in a meeting hall
  • Poster presentation with spotlight talk (about 6 minutes including Q&A) at an E-Poster station in the poster area. Spotlight presenters will be requested to both bring a printed poster and submit an E-Poster of their abstract.
  • Poster viewing within the on-site poster area. Presenting authors of abstracts selected for poster viewing will be requested to both bring a printed poster and submit an E-Poster for electronic viewing. There will be no designated presentation time for poster viewing. Instead, authors are kindly requested to visit the on-site poster area during longer programming breaks and interact with other delegates.

Basic Information

  • Presenting author’s contact details
  • Author(s) names appear in upper and lower case (e.g. J.C. Smith).
  • Author and co-authors’ affiliation details: department, institution/organisation, city, state (if relevant), country.
  • Abstract title – The title is limited to 25 words in UPPER CASE (e.g. EVALUATING VACCINE IMPACT)
  • Abstract text – The text is limited to 250 words, including acknowledgments (if any). The text count may be affected by inserting tables and non-scientific text such as acknowledgments.
  • Abstract topic – Abstracts must be allocated to a specific topic for the Scientific Programme. Please choose from the list of topics.
  • Keywords – Please enter 1 to 5 keywords that define your abstract. The keywords must be in English and can include numbers.
  • Images, graphs, tables – The maximum file size of each image is 500 KB. The maximum pixel size of the graph/image is 600(w) x 800(h) pixels. You may upload images in JPEG/JPG or PNG format only.
  • Conflict of interest disclosure – At the time of submission, the submitting author will be requested to provide a brief conflict of interest statement on behalf of all co-authors. If the abstract is selected for presentation, the presenting author will be contacted additionally to complete a mandatory Conflict of Interest Disclosure form.


  • The author designated as the presenter for an abstract accepted into the ISPPD-13 scientific programme must be a registered participant. Presenting authors must register by 6 December 2023 in order to confirm their participation in the Meeting. Abstracts of unregistered presenting authors will be removed from the final scientific programme. In case of a change in the presenting author after submission has closed, please immediately notify the Meeting Organisers at isppd_abstracts@kenes.com.
  • Submission of an abstract acknowledges your acceptance for the abstract to be published in the official meeting publications.
  • The presenting author is required to ensure that all co-authors are aware of the content of the abstract and agree to its submission, before submitting the abstract.
  • All accepted abstracts may be published in a peer-reviewed journal in addition to the meeting website. If such publication is confirmed, further details will be posted on the ISPPD-13 website.
  • Abstract submitters will be required to disclose any conflict of interest in the submission form.
  • Use only standard abbreviations. Place special or unusual abbreviations in parentheses after the full word the first time it appears.
  • Use generic names of drugs. The presentation must be balanced and contain no commercial promotional content.
  • Submissions may not contain patient names, hospital ID numbers, or other identifying information.
  • The submission form allows you to store your abstract as a DRAFT until the deadline (12 September 2023). After the deadline if not submitted, drafts will be deleted.
  • Before the abstract submission deadline, you may reopen and edit your abstract if necessary. Click on the SUBMIT button at the end of the process in order to submit your abstract. Changes will not be possible to your abstract after the submission deadline.
  • You will receive an abstract ID number via email after you have submitted your abstract. Please refer to this abstract ID in all correspondence regarding the abstract.
  • Please contact us if you have not received confirmation that your abstract has been submitted.
  • Please do not submit multiple copies of the same abstract.


During abstract submission, you will be asked to confirm that you agree to the following:

  1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after final submission and I am aware that it will be published as submitted.
  2. Submission of the abstract constitutes the consent of all authors to publication (e.g. meeting website, programmes, other promotions, etc.)
  3. The Abstract Submitter warrants and represents that no part of the information and content provided by him/her (Hereafter: the “Content“) to the 13th Meeting of the International Society of Pneumonia and Pneumococcal Diseases (ISPPD-13) and Kenes International Organizers of Congresses SA and its affiliates (together: the “Organisers“), nor the publication of any such Content by each of the Organisers, on the internet or otherwise infringes any third party rights, including but not limited to privacy rights and/or intellectual property rights.
  4. The Abstract Submitter grants each of the Organisers the license and right to use, reproduce, publish, translate, distribute, and display the Content or any part thereof, in any manner and on any platform or media whatsoever, in each Organiser’s absolute discretion, on a royalty-free, perpetual, irrevocable nonexclusive basis.
  5. I herewith confirm that the contact details saved in this system are those of the presenting author, who will be notified about the status of the abstract. The presenting author is responsible for informing the other authors about the status of the abstract. The submitting author may request to be copied on abstract correspondence.
  6. I understand that the presenting author must be a registered participant.
  7. The Organisers reserve the right to remove from publication and/or presentation an abstract that does not comply with the above.
  8. I understand that I must select a specific Theme, Topic and/or Sub-Topic for my abstract allocation. Although the Committee will work hard to honor this selection, this cannot be guaranteed. The Committee reserves the right to change the Theme, Topic or Sub-Topic under which the abstract was originally submitted.


Abstract titles and author names of abstracts selected for oral and spotlight poster presentations will be visible via the ISPPD-13 interactive programme in their designated sessions once the notification process has been completed. The abstract bodies of abstracts accepted for oral presentation will be visible via the interactive programme one week before the Meeting.

All abstracts* submitted and accepted for presentation during the regular and late-breaking submission period will be released one week before the Meeting (11 March 2024) via the ISPPD-13 mobile application accessible to registered attendees.

On the first day of the Meeting, all accepted abstracts* will be published on the ISPPD-13 website here.

The embargo on abstracts submitted to the ISPPD-13 Meeting is officially lifted on the first day of the meeting (17 March 2024). E-Posters submitted to ISPPD-13 remain under embargo for 3 months after the meeting (until 20 June 2024) and will be accessible to registered attendees via the ISPPD-13 Virtual Platform.

*Please note that only abstracts of registered presenting authors are included in the ISPPD-13 scientific programme.


During the abstract submission, you have the option to apply for a Travel Grant and/or an Abstract Award for Young Investigators. Please carefully read the below guidelines and prepare the required documentation before submitting your application.


ISPPD-12 Robert Austrian Research Award winners (both 2020 and 2022 funding rounds) must submit an abstract to the ISPPD-13 Meeting (Cape Town, 2024) to indicate the progress of the research project for which they were awarded. Upon submission, ISPPD-12 RARA winners should contact the Meeting Organisers via email at isppd@kenes.com and specify the abstract ID and title corresponding to the research project for which they were awarded.